Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      β-Adrenergic Receptors in Congestive Heart Failure: Present Knowledge and Future Directions

      ,

      Cardiology

      S. Karger AG

      β-Adrenergic receptors, Congestive heart failure, Norepinephrine

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In recent years substantial information has become available on the function and regulation of β-adrenergic receptors in experimental model systems and in the human heart. β-Adrenergic receptors mediate the positive inotropic and chronotropic effects of the sympathetic neurotransmitter norepinephrine in the heart. They can be altered in various disease states including congestive heart failure. In order to enhance understanding of β-adrenergic receptor regulation in heart failure, we here review the present knowledge and the open question in three areas: (1) the differential role of β<sub>1</sub>- and β<sub>2</sub>-adrenergic receptors; (2) regulation of the number of cardiac β-adrenergic receptors by drugs and disease states, and (3) regulation of the responsiveness of cardiac β-adrenergic receptors.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          978-3-8055-5110-6
          978-3-318-01704-5
          0008-6312
          1421-9751
          1989
          1989
          12 November 2008
          : 76
          : 5
          : 338-346
          Affiliations
          Departments of Medicine and Pharmacology, University of California, San Diego, and Veterans Administration Medical Center, La Jolla, Calif., USA
          Article
          174517 Cardiology 1989;76:338–346
          10.1159/000174517
          2557152
          © 1989 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 9
          Categories
          Heart Failure

          Comments

          Comment on this article